New JAMA Network Open study: GLP-1 meds (semaglutide, tirzepatide) linked to:
37% â dementia risk
19% â ischemic stroke risk
30% â mortality
Most benefit: age 60+, women, BMI 30â40. Observational, not causal, but promising for brain & heart health.
about 2 months ago